Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 51 of 56 for:    stem cell Spinal Cord Injury AND cells

Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01765803
Recruitment Status : Terminated (Primary objective not met after planned interim analysis)
First Posted : January 10, 2013
Results First Posted : July 20, 2015
Last Update Posted : April 14, 2016
Sponsor:
Collaborator:
Oxnard Foundation
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance

Tracking Information
First Submitted Date  ICMJE January 8, 2013
First Posted Date  ICMJE January 10, 2013
Results First Submitted Date  ICMJE June 19, 2015
Results First Posted Date  ICMJE July 20, 2015
Last Update Posted Date April 14, 2016
Study Start Date  ICMJE June 2013
Actual Primary Completion Date November 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 15, 2016)
CD34+ Progenitor Cell Mobilization [ Time Frame: 8 hours following treatment ]
To measure CD34+ cells, a peripheral blood draw is taken from the enrolled subject at hour zero on day one of the study before treatment with oral thioridazine. Following treatment, blood draws are taken at 2, 4, 8 and 24 hours. These blood samples are analyzed using Clinical Laboratory Improvement Amendments (CLIA)-approved flow cytometry for CD34+ cell content. CD34+ cell levels will be reported as a percentage of total white blood cells (WBC) in the blood specimens and the difference between baseline and 8 hours will be reported
Original Primary Outcome Measures  ICMJE
 (submitted: January 9, 2013)
CD34+ Progenitor Cell Mobilization [ Time Frame: 24 hours ]
To determine the dose-related CD34+ progenitor cell mobilization by thioridizine when administered as a single agent in normal (healthy) study subjects
Change History Complete list of historical versions of study NCT01765803 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 19, 2015)
Toxicity [ Time Frame: Up to 1 month after treatment ]
Toxicity will be evaluated according to the grading system (0-5) NCI CTCAE (Common Terminology Criteria for Adverse Events) version 4. Any subject who receives treatment on this protocol will be evaluable for toxicity.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 9, 2013)
Measure side effects [ Time Frame: 1 month ]
To describe the adverse events associated with thioridizine when administered as a single, 50 mg dose in healthy study subjects according to CTCAE version 4.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
Official Title  ICMJE A Single Institution Feasibility Study to Assess Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
Brief Summary This study will investigate the possibility of using the drug thioridazine (also called Mellaril) to increase the number of certain types of cells moving from the bone marrow to the circulation in a group of healthy humans. The types of cells we hope to collect are called CD34+ progenitor, or stem cells. These cells can be used in the laboratory to better understand a number of diseases and suggest new strategies for therapy. Perhaps the most important potential application of human stem cells is the generation of cells and tissues that could be used for cell-based therapies, as a renewable source of replacement cells and tissues to treat diseases including Alzheimer's diseases, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.
Detailed Description This is a single-arm, feasibility study to test whether a single dose of Mellaril (thioridazine HCL) is able to effectively mobilize CD34+ cells in a set of health human subjects. This study does not involve the use of placebos, and subjects will serve as their own controls for CD34+ cell mobilization. We hypothesize that a single dose of Mellaril (thioridazine HCL) will mobilize CD34+ progenitor cells into human peripheral blood by a factor of at least 10 fold, from 4 to 40 cells/microliter.
Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Condition  ICMJE Healthy Subjects
Intervention  ICMJE Drug: Mellaril
Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
Other Name: Thioridazine
Study Arms  ICMJE Experimental: Mellaril (thioridazine)
A single 50 gm dose of thioridizine (Mellaril) will be given orally at the beginning of the study
Intervention: Drug: Mellaril
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: December 5, 2013)
6
Original Estimated Enrollment  ICMJE
 (submitted: January 9, 2013)
10
Actual Study Completion Date  ICMJE December 2013
Actual Primary Completion Date November 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy, non-smoking subjects (male or female)
  • Age: 18 to 55 years
  • All subjects must agree to refrain from consuming alcohol during for 48 hours after taking thioridazine.
  • Performance status Karnofsky score of 100%.
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • A female of child-bearing potential is any woman (regardless of sexual orientation, having not undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
  • Has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  • Ability to understand the purpose and procedures of this study, and the willingness to sign a written informed consent document.
  • Only subjects whose laboratory testing, including platelet counts and transaminase levels are within normal limits are eligible.
  • Subjects must pass pre-treatment screening by EKG to rule out long QT syndrome or subclinical cardiac arrhythmia.

Exclusion Criteria:

  • Subjects who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Agent(s) or other agents used in study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, a febrile illness within 35 days of study entry, or psychiatric illness or dementia, or social situations that would limit compliance with study requirements.
  • Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
  • Concomitant use of phenytoin excludes potential subjects from participation.
  • Subjects with known long QT syndrome or known history of cardiac arrhythmias are excluded from participation.
  • Subjects taking drugs known to inhibit P450 CYP2D6 are excluded from participation.
  • Subjects who received an investigational agent within 28 days of dosing with thioridazine on this protocol are excluded from participation.
  • Subjects who received thioridazine within 7 days of dosing on this protocol are excluded from participation.
  • Subjects who have had pelvic radiation are excluded from participation.
  • Subjects who have received myeloablative regimens at any time are excluded from participation.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01765803
Other Study ID Numbers  ICMJE INST 1208
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party New Mexico Cancer Care Alliance
Study Sponsor  ICMJE New Mexico Cancer Care Alliance
Collaborators  ICMJE Oxnard Foundation
Investigators  ICMJE
Principal Investigator: Stuart S Winter, MD University of New Mexico Health Sciences Center/Pediatric Oncology
PRS Account New Mexico Cancer Care Alliance
Verification Date March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP